ALMIRALL S.A. EO -_12
Commented by Nico Popp on September 9th, 2026 | 07:30 CEST
Biotech Boom Thanks to Synergies: AstraZeneca Bets on Platforms, Almirall Forges Alliances, and Vidac Pharma Has the Multi-Tool
Everyone in Germany knows the situation: doctors' offices are crowded, and the healthcare system is stretched to its limits. But even when waiting rooms are full, there are still rays of hope. In Europe, research is being conducted successfully in many areas. As standard drugs gradually lose their patent protection, a new era is dawning. While cutting-edge research in Germany is still considered brilliant, it has all too often failed to translate findings into products. But that is changing. A new generation of European pharmaceutical players is closing the gap with the competition and showing that groundbreaking therapeutic advances no longer have to come exclusively from overseas. We take a look at some exciting companies.
Read
Commented by Nico Popp on March 3rd, 2026 | 07:40 CET
Paradigm shift in oncological dermatology: Vidac Pharma as an innovator, what are Almirall and Biofrontera doing?
Oncological dermatology is on the cusp of a revolution that could fundamentally change our understanding of cancer treatment. Persistence Market Research estimates that the global market for the treatment of actinic keratosis will reach a volume of around USD 7 billion by 2026. Analysts expect the market to grow to between USD 11.1 and 14.45 billion by the mid-2030s. This momentum is driven by the aging global population, cumulative UV exposure due to changing leisure habits, and increased awareness of the dangers of skin cancer. Currently, established industry giants such as Almirall and Biofrontera dominate the standard of care for actinic keratosis with their proven products. However, Vidac Pharma marks the transition from merely combating symptoms to a revolutionary procedure in oncological dermatology. This makes the company an opportunity for growth-oriented investors seeking access to a completely new class of drugs in the field of metabolic oncology.
Read